LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.520
-0.010 (-0.65%)
Aug 14, 2025, 8:22 AM - Market open
LAVA Therapeutics Employees
LAVA Therapeutics had 34 employees as of December 31, 2024. The number of employees decreased by 3 or -8.11% compared to the previous year.
Employees
34
Change (1Y)
-3
Growth (1Y)
-8.11%
Revenue / Employee
$146,765
Profits / Employee
-$833,176
Market Cap
39.99M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34 | -3 | -8.11% |
| Dec 31, 2023 | 37 | -32 | -46.38% |
| Dec 31, 2022 | 69 | 11 | 18.97% |
| Dec 31, 2021 | 58 | 27 | 87.10% |
| Dec 31, 2020 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LVTX News
- 16 hours ago - LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 3 months ago - LAVA Reports First Quarter 2025 Financial Results, Provides Business Update - GlobeNewsWire
- 4 months ago - LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation - GlobeNewsWire
- 4 months ago - LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - GlobeNewsWire
- 5 months ago - Analyst Downgrades LAVA Therapeutics, Sees Pipeline Overhang - Benzinga
- 7 months ago - LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers - GlobeNewsWire
- 8 months ago - LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027 - GlobeNewsWire
- 1 year ago - LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire